Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review
暂无分享,去创建一个
F. Baltazar | F. Pinto-Ribeiro | J. Afonso | Beatriz Rosa | Ana Silva | Mónica Costa Cerqueira | Catarina Sobral | Marta Freitas Costa | Julieta Afonso
[1] A. Le,et al. Glucose Metabolism in Cancer: The Warburg Effect and Beyond , 2022, Advances in experimental medicine and biology.
[2] Ziqin Deng,et al. Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy , 2022, Frontiers in Cell and Developmental Biology.
[3] Wei Li,et al. Lactylation, an emerging hallmark of metabolic reprogramming: Current progress and open challenges , 2022, Frontiers in Cell and Developmental Biology.
[4] J. Väyrynen,et al. Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors , 2022, Cancers.
[5] F. Baltazar,et al. In Vivo Anticancer Activity of AZD3965: A Systematic Review , 2021, Molecules.
[6] Qiuhong Yang,et al. Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma , 2021, Clinical and Experimental Medicine.
[7] Pei Zhang,et al. Lactate in the tumour microenvironment: From immune modulation to therapy , 2021, EBioMedicine.
[8] G. Úrrutia,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. , 2021, Revista espanola de cardiologia.
[9] R. Reis,et al. MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma , 2021, Cancers.
[10] A. Longatto-Filho,et al. Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin , 2021, Frontiers in Oncology.
[11] M. Dyer,et al. Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). , 2021 .
[12] J. Kauppila,et al. Monocarboxylate Transporters 1 and 4 and MTCO1 in Gastric Cancer , 2021, Cancers.
[13] B. Firestein,et al. Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation , 2021, Cells.
[14] J. Ferlay,et al. Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.
[15] K. Ueda,et al. Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma , 2021, Cancers.
[16] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[17] L. Fang,et al. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer , 2021, Translational cancer research.
[18] M. Canis,et al. Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome , 2021, Scientific Reports.
[19] Tong Li,et al. Prognostic implications of combined high expression of CD47 and MCT1 in breast cancer: a retrospective study during a 10-year period , 2021, Translational cancer research.
[20] D. Rassl,et al. Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report) , 2020, Journal of translational medicine.
[21] Yang Liu,et al. Role of Proton-Coupled Monocarboxylate Transporters in Cancer: From Metabolic Crosstalk to Therapeutic Potential , 2020, Frontiers in Cell and Developmental Biology.
[22] M. Morris,et al. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model , 2020, The AAPS Journal.
[23] K. Juvale,et al. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights. , 2020, European journal of medicinal chemistry.
[24] F. Baltazar,et al. Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy , 2020, Frontiers in Oncology.
[25] Ç. Biray Avcı,et al. Crucial Players in Glycolysis: Cancer Progress. , 2020, Gene.
[26] Xiaomei Lu,et al. Clinicopathological and prognostic involvements of MCT1, MCT4 and IL7R in esophageal squamous cell carcinoma , 2019 .
[27] C. Frezza. Metabolism and cancer: the future is now , 2019, British Journal of Cancer.
[28] C. Lebbé,et al. CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker , 2019, Cancers.
[29] J. Manzo-Merino,et al. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches , 2019, Front. Oncol..
[30] M. Kojima,et al. Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma. , 2019, Pancreas.
[31] E. Nice,et al. MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling , 2019, Cell Death & Disease.
[32] Pierre Sonveaux,et al. Monocarboxylate transporters in cancer , 2019, Molecular metabolism.
[33] Arslaan Javaeed,et al. MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis , 2019, Oncology reviews.
[34] J. Quinn,et al. The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer , 2019, International journal of cancer.
[35] W. Zhou,et al. Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma. , 2019, Oncology reports.
[36] A. Longatto-Filho,et al. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma , 2019, Cellular Oncology.
[37] M. Morris,et al. In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model , 2018, The AAPS Journal.
[38] Changhua Wang,et al. Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets. , 2018, Biochemical and biophysical research communications.
[39] Guiming Zhang,et al. MCT1 regulates aggressive and metabolic phenotypes in bladder cancer , 2018, Journal of Cancer.
[40] C. Scapulatempo-Neto,et al. The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors , 2018, Oncotarget.
[41] Wei Zhang,et al. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. , 2018, Urologic oncology.
[42] I. Stratford,et al. Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer , 2017, BMC Clinical Pathology.
[43] P. Porporato,et al. Cancer metabolism in space and time: Beyond the Warburg effect. , 2017, Biochimica et biophysica acta. Bioenergetics.
[44] B. Leiby,et al. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. , 2017, Seminars in oncology.
[45] S. Halford,et al. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. , 2017 .
[46] A. Giatromanolaki,et al. Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis , 2017, Experimental lung research.
[47] Shuyi Zhang,et al. MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer. , 2017, Biochemical and biophysical research communications.
[48] J. Palazzo,et al. MCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer , 2017, Front. Cell Dev. Biol..
[49] P. Lehenkari,et al. Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma , 2017, Oncotarget.
[50] J. Rodrigo,et al. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation , 2017, Oncotarget.
[51] G. Brooks,et al. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect , 2016, Carcinogenesis.
[52] I. Novak,et al. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells , 2016, Pancreas.
[53] P. Liu,et al. Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment. , 2016, Oncology reports.
[54] A. Longatto-Filho,et al. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis , 2016, BMC Cancer.
[55] A. Longatto-Filho,et al. Prognostic significance of monocarboxylate transporter expression in oral cavity tumors , 2016, Cell cycle.
[56] A. Longatto-Filho,et al. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4 , 2016, Cell cycle.
[57] R. Montironi,et al. Metabolic phenotype of bladder cancer. , 2016, Cancer treatment reviews.
[58] A. Longatto-Filho,et al. Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness , 2016, Cell cycle.
[59] C. Thompson,et al. The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.
[60] U. Martinez-outschoorn,et al. Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis , 2015, BioMed research international.
[61] A. Longatto-Filho,et al. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors , 2015, Oncotarget.
[62] A. Longatto-Filho,et al. CD147 and MCT1‐potential partners in bladder cancer aggressiveness and cisplatin resistance , 2015, Molecular carcinogenesis.
[63] Toshio Matsumoto,et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation , 2015, Oncotarget.
[64] Y. Nordby,et al. Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure. , 2015, Urologic oncology.
[65] Fan Yang,et al. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. , 2015, International journal of clinical and experimental pathology.
[66] Stephanie M. Tortorella,et al. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K , 2015, Molecular Biology Reports.
[67] Hushan Yang,et al. Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer , 2015, Tumor Biology.
[68] R. Deberardinis,et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. , 2014, Cell reports.
[69] E. Richardsen,et al. Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival , 2014, PloS one.
[70] A. Longatto-Filho,et al. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. , 2014, World journal of gastroenterology.
[71] Ju-Han Lee,et al. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. , 2014, Urology.
[72] F. Baltazar,et al. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer , 2014, BMC Cancer.
[73] R. Reis,et al. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization , 2014, Journal of Translational Medicine.
[74] Paul D. Smith,et al. Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[75] F. Baltazar,et al. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer , 2013, The Prostate.
[76] A. Halestrap. The SLC16 gene family - structure, role and regulation in health and disease. , 2013, Molecular aspects of medicine.
[77] J. Verrax,et al. Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells , 2012, PloS one.
[78] M. Weller,et al. Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death , 2012, Oncogene.
[79] A. Carvalho,et al. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs) , 2012, Journal of Bioenergetics and Biomembranes.
[80] Franziska Hirschhaeuser,et al. Lactate: a metabolic key player in cancer. , 2011, Cancer research.
[81] Adam Ertel,et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors , 2011, Cell cycle.
[82] P. Fortina,et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.
[83] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[84] Julien Verrax,et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.
[85] D. Sabatini,et al. Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.
[86] O. Warburg,et al. THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.
[87] F. Baltazar,et al. Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect. , 2020, Advances in experimental medicine and biology.
[88] F. Baltazar,et al. New horizons on pH regulators as cancer biomarkers and targets for pharmacological intervention , 2020 .
[89] Ju-Han Lee,et al. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. , 2015, Human pathology.
[90] Yuanzhong Wu,et al. Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway. , 2014, Cancer letters.
[91] H. Izumi,et al. Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. , 2012, Experimental and therapeutic medicine.